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This thesis studies the effects of intra-aortic balloon counter-pulsation (IABP) treatment 
on the visceral arterial circulation, together with an evaluation of the optimal weaning 
strategy from this hemodynamic mechanical support modality. 
IABP treatment in its current form has been used in the clinical setting for decades, but 
despite the long experience of the cardiovascular society with this therapy, IABP is still 
associated with a significant complication rate. One of the potential lethal complications 
of IABP treatment is visceral ischemia, potentially due to obstructive or non-obstructive 
positioning of the IABP-catheter. In this thesis, we further elucidated the effect of optimal 
positioned intra-aortic balloon (IAB) on visceral arterial flows and its potential for 
optimization of IABP catheter use and design in a porcine model. 
The general background and introduction to the studies presented in this thesis are 
provided in Chapter 1. 
In Chapter 2 we have explored the arterial waveform patterns in the visceral circulation 
during IABP support. In an animal study, we found that the wave patterns in both the 
mesenteric and the renal arterial vasculature, although to a lesser extent, are altered due 
to IABP therapy. The wave pattern in the superior mesenteric artery (SMA) showed an 
immediate drop in arterial flow during early and mid-diastole, while there was a sudden 
rise in flow in late diastole. In the systolic phase the flow increased again, but remained 
lower than baseline. We postulated that the origin of these effects are threefold: 1) a 
direct intrinsic (myotonic) negative feedback mechanism of the smooth muscle cells in 
the wall of the SMA leading to vasoconstriction following the rise in vascular pressure due 
to balloon inflation; 2) an increase in baroreceptor response due a diphasic output wave 
following diastolic balloon augmentation; 3) a reversal of energy stored in the elastic 
aortic wall following balloon inflation in diastole leading to an increase in SMA flow in late 
diastole. When studying both left and right renal flows, it was observed that flows in both 
arteries were similar during all phases of IABP support. However, the arterial flow in early 
diastole was not altered, but decreased significantly in mid diastole, followed by a 
significant late diastolic increase ending with a non-significant increase during systole. 
Although an alteration in baroreceptor response and a reversal of energy stored in the 
arterial vascular wall could also be applicable for the renal situation, theoretically there 
could not have been any local autoregulatory influence at the renal arterial vasculature 
since mean arterial pressures were kept above its lower tress hold level of 60 mmHg. 
Following the observations made in this chapter, there might be room for new triple-
segmented and dual-chambered new balloons. These catheters have been designed in 
the past, but never found the way to the clinical setting. This study thus advocates for a 
renewed discussion about the necessity for new IAB designs. 
Chapter 3 gave us more insight in the effect of variable balloon volumes on IABP 
performance. The optimal weaning strategy (i.e. a volume-based weaning strategy or a 
rate-based weaning strategy) still remains subject of discussion. Therefore, animal 
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experiments were performed, comparing these two different IABP weaning strategies. 
Weaning by progressive volume deflation showed significant hemodynamic effects: a 
greater degree of vasodilation, better cardiac output and stroke volume, less negative 
values of cardiac cycle efficiency, and a higher dP/dTmax compared with those weaned by 
rate-reduction. Furthermore, volume based weaning exhibited increased coronary flow, 
lower oxygen consumption of the myocardium, a lower coronary resistance and lower 
serum lactate levels. 
Our findings thus suggest that a volume-based weaning strategy is thus preferable, 
leading to hemodynamic, coronary and metabolic advantages.  
Malpositioning of IABP is a common cause of visceral artery compromise, potentially 
leading to occlusive mesenteric ischemia. However, even when positioned correctly, 
strictly adhering to manufacturer’s implantation protocols, conventional intra-aortic 
balloons will lead to a so-called anatomic-to-device mismatch in 70% of patients treated 
as observed on CT-scans. Shorter balloons might thus be beneficial. In Chapter 4 to 7 we 
dove into the concept of shorter-sized IABP and balloon volumes using four different 
balloon catheters (Zeon Medical Inc., Tokyo, Japan) in a porcine model of ischemia-
reperfusion. The used catheters were a two conventional ‘longer’ 35- and 40-mL 
catheters, together with a yet clinically available 40-mL and a prototype 35-mL ‘short’ 
catheter. 
In Chapter 4, we described a proof-of-principle study evaluating two new short-sized IAB 
catheters (35-mL and 40-mL) vs. unsupported controls. All animals showed a significant 
decrease in superior mesenteric artery (SMA), and left and right renal blood flows during 
2 hours of myocardial ischemia in comparison with baseline. However, both 
interventional groups showed a significant improvement in SMA and renal blood flows, 
remaining constant in comparison with the control group. After 6 hours of reperfusion 
only the renal blood flows returned to baseline levels, whereas SMA blood flows 
remained just a fraction lower than baseline. Hemodynamic improvements were 
observed in both IABP groups following reperfusion in comparison with controls, which 
also translated in coronary circulatory benefits: reduced coronary vascular resistance and 
myocardial oxygen demand in conjunction with increased myocardial oxygen supply. 
Since we used fluoroscopy to guarantee non-occlusive IABP placement, we postulate that 
these favourable effects are partly due to enhanced vasomotor control effects similarly 
observed in situations of haemorrhagic shock. 
From this proof-of-concept study we learned that a short IABP balloon comes with the 
well-known beneficial properties of counterpulsation in terms of hemodynamics and 
coronary circulation, but also enhanced visceral flow as compared to control animals not 
receiving IABP therapy. Nonetheless, if from one side the shorter balloon length is 
advantageous in order to prevent visceral ischemia, its hemodynamic and coronary 
circulatory might be less efficacious due to the shorter length if compared with a normal 
length balloon catheter. 
Summary 
169 
Chapter 5 was thus aimed at comparing a short and a standard-sized balloon with same 
filling volumes (40 mL) in order to verify the differences regarding visceral flow, coronary 
circulation and hemodynamic performance during aortic counterpulsation in a porcine 
model of myocardial ischemia-reperfusion injury. Again, an unsupported control group 
was added for validation purposes, while fluoroscopy was used to rule out that any 
observations made during this study were related to an obstructive origin. The SMA blood 
flow was increased by short IAB therapy and reduced by standard-balloon support, even 
when indexing for changes in mean arterial pressure, mean vascular resistances and 
cardiac output. From a mechanical viewpoint, we hypothesized that the standard-sized 
balloons, being longer and ending closer to the ostium of the SMA, create a more 
turbulent flow at the ostium of the SMA. Given the fact that a non-laminar blood stream 
increases the perfusion pressure required to drive a given flow, it is possible that even at 
comparable perfusion pressures, intra-aortic turbulence, induced by the presence of a 
standard IABP balloon close to the vessel orifice, would lead to a decrease in flow. 
Another explanation for this finding, could be that, the greater expansion of the short 
balloon due to its larger diameter, might translate into a greater energy stored in the 
elastic tissues of the aorta, and transmitted back to the column of blood interposed 
between the arterial wall and the balloon surface. Finally, we postulated that the height 
of the blood column comprised between the balloon`s tip and the SMA ostium in the 
short balloon is larger, leading to greater perfusion pressure and, consequently, higher 
SMA blood flows. From a neuro-endocrine standpoint it could be hypothesized that 
activation of aortic baro-receptors inhibiting the medullary vasoconstrictor reflex and a 
higher arterio-venous gradient, both due to increased diastolic blood pressures, 
contribute to this finding. Renal blood flows increased during IABP treatment in both 
standard-sized and short-balloon subjects, but these improvements were significantly 
higher in short balloon subjects in comparison with the standard-sized balloons. This 
could be explained by similar mechanical explanations as given for SMA flows. Given the 
beneficial effects of the short balloon on the visceral circulation, we found that these 
favourable effects were not at expense of hemodynamic or coronary performances. The 
short balloon showed comparable result to the standard-sized balloon in terms of cardiac 
output, systemic vascular resistance and dp/dTmax cardiac cycle efficiency throughout the 
experiment. Furthermore, the short balloon reduced the myocardial vascular resistance 
and myocardial oxygen consumption, while at the same time increasing, coronary blood 
flow with no difference with the standard balloons. This was likely to be related to the 
balloon volume and, therefore, to the same amount of blood volume displaced by the 
two different balloons, resulting in comparable diastolic pressure augmentation. 
Concluding: shorter-sized IAB-catheters with similar volumes might create less visceral 
perfusion disturbances, while maintaining classic IABP supportive effects.  
In Chapter 6 we have investigated whether the prototype 35-mL short IAB could be a 
suitable option for non-small sized patients, potentially reducing the occurrence of in- 
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hospital complications related to the balloon size. Therefore, we compared the effects of 
a prototype 35-mL short IAB with a conventional length 40-mL IAB. In this chapter we 
aimed at demonstrating not only that the prototype 35-mL balloon does not impair 
visceral circulation, but compared to the standard-sized higher volume (40 mL) IAB 
balloon, it does not lose its hemodynamic augmentation benefits. The use of a 35-mL 
short balloon was associated with a significant improvement in visceral flows. The animals 
allocated to the 35-mL short balloon group showed a significant increase in SMA flows, 
while a standard 40-mL IAB catheter was associated with a significant decrease in SMA 
flows. After reperfusion the renal flows increased in both studied groups, although this 
was to a significantly greater extent in the 35-mL short IABP balloon. Since both 35-ml 
short and 40-ml short balloons differ only 11 mm in length and 0.4 mm in diameter, 
similar mechanical and neuro-endocrine explanations as proposed in chapter 4 can 
account for these effects.  
Interestingly the hemodynamic and coronary performance of this shorter, less 
voluminous balloon showed comparable results in comparison with the standard-sized 
balloons as reflected in cardiac output, systemic vascular resistance, dp/dTmax, coronary 
blood flows and myocardial oxygen consumption. Beforehand, the 40-mL-standard-sized 
IAB catheter would be expected to result in greater diastolic pressure augmentation 
because it is likely to move a greater amount of blood volume. We hypothesized that the 
greater expansion of the short balloon, because of its larger diameter (17.1 mm vs 15.1 
mm in the 40-mL standard balloon), might translate into a greater energy stored in the 
elastic tissues of the aorta and transmitted back to the column of blood interposed 
between the arterial wall and the balloon surface, which needs to be further elucidated 
in future in-vitro studies. 
While we found that there were no significant differences in the hemodynamic and 
coronary performance of the prototype 35-mL short balloon vs. the conventional 40-mL 
IAB balloon in chapter 6, questions arose about the potential of the currently to the 
market available 35-mL long catheter. Although this catheter comes with a substantial 
shorter balloon in comparison with its 40-ml equivalent (214 mm vs. 243 mm) the 
diameter of this balloon is similar (15.1 mL). In comparison with the shorter catheters 
(35-mL: 162 mm vs. 40-mL: 173 mm) they are still considerably longer. Therefore, we 
studied the effect of this slightly shorter 35-mL conventional IABP balloon on the visceral 
circulation in comparison with the 35-ml short, 40-ml short and 40-ml long IABP catheters 
in a similar model of ischemia-reperfusion in Chapter 7. 
During the reperfusion phase we found that the use of a 35-ml long balloon catheter, 
although being 29 mm shorter than its 40-mL equivalents, did not allow any increase in 
SMA flows throughout the whole experiment even when indexed for alterations in 
cardiac output, blood pressures or vascular resistances and thus shared similar behaviour 
as the 40-mL long IABP catheter. The 29 mm difference in length might theoretically still 
be insufficient to result in a return of laminar blood flow at the origin of the SMA, as 
Summary 
171 
proposed in chapter 5, but requires further in-vitro testing. Again, similar to the 
observations made in chapter 5, renal flows increased during the course of IABP therapy, 
but again showed to increase to a greater extent in the short-balloon groups in 
comparison with the longer ones. Since the mean arterial pressures remained stable 
above the minimum level necessary for the autoregulatory mechanisms of the kidney 
throughout the whole experiment, these observations regarding renal flows are most 
likely explained to be due to mechanical IABP effects. Furthermore, there were no 
significant intra-group differences observed in either the standard-sized or short balloon-
groups, giving rise to the idea that either the shorter length of the shorter balloon 
catheters or the increased diameters determine the increase in renal flows, which could 
be subject to further research. The 35-mL long balloon improved hemodynamics and use 
of such showed beneficiary effects for the coronary circulation to a similar extent as the 
shorter and larger-volume balloons. Therefore, from this chapter we conclude that 
changes in visceral perfusion during IABP support are significantly related to balloon 
length and not to a small (5cc) change in volume. 
Finally, a general discussion of the results and findings of this thesis and an explanation 
of their implications on future IABP research, catheter design and therapy are discussed 
in Chapter 8. 
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Dit proefschrift onderzoekt de effecten van de intra-aortale ballonpomp (IABP) op de 
viscerale bloedvoorziening. IABP is een invasieve mechanische ondersteuningsmodaliteit, 
welke reeds decennia gebruikt wordt in de klinische praktijk. Net als iedere invasieve 
mechanische ondersteuningsmodaliteit is het gebruik van deze techniek geassocieerd met 
serieuze complicaties. Één van deze complicaties betreft het ontwikkelen van viscerale 
ischemie ten gevolge van obstructieve, maar ook non-obstructieve plaatsing van de IABP-
katheter. In dit proefschrift gaan we dieper in op de viscerale effecten van optimaal 
geplaatste (non-obstructieve) IABP-katheters. Daarnaast wordt besproken welke 
optimalisaties in het gebruik van deze ondersteuningsmodaliteit doorgevoerd kunnen 
worden om dit complicatierisico te beperken. 
IABP-therapie wordt reeds decennia gebruikt om patiënten met een cardiogene shock 
tijdelijk te ondersteunen middels een ballonkatheter. Deze wordt meestal ingebracht via 
één van de femoralis arteriën in de aorta descendens, net 2 cm onder de linker arteria 
subclavia. Indien deze katheter is ingebracht zal deze ervoor zorgen dat de coronaire 
perfusie verbetert gedurende diastole door het gesynchroniseerd opblazen van de ballon 
op deze katheter. In deze kritieke periode van cardiogene shock wordt zo de perfusie van 
de coronairen verbeterd. Daarnaast zorgt deze techniek ervoor dat de weerstand 
waartegen het hard moet pompen (‘afterload’) verminderd wordt ten tijde van systole, 
door het snelle leeglaten van dezelfde ballon. 
Een algemene uitleg over de fysiologische achtergrond van IABP-ondersteuning, 
indicaties, contra-indicaties en viscerale complicaties tezamen met de doelstellingen voor 
dit proefschrift wordt gegeven in hoofdstuk 1.  
In hoofdstuk 2 gaan we in op de ‘golfpatronen’ (i.e. ‘wave patterns’) in de arteria 
mesenterica superior (AMS) en de beide nier-arteriën. In proefdieronderzoek laten we 
zien dat deze ‘wave patterns’ in de AMS meer worden aangedaan dan die van de nier-
arteriën. Derhalve is er mogelijk ruimte voor een hernieuwde discussie van het gebruik 
en ontwikkelen van gesegmenteerde IABP-katheters om deze interferentie met de 
viscerale perfusie te verminderen. 
In hoofdstuk 3 verkrijgen we meer inzicht in de werking van IABP door het variëren van 
de ballonvolumina in het geleidelijke afbouwen van deze ondersteuning (‘weaning’). 
Algemeen genomen kan er middels een geleidelijke afbouw van volume van de ballon op 
de katheter, danwel geleidelijke aanpassing van de ondersteuningsratio (van 1:1; naar 1:2 
etc.) IABP-ondersteuning worden afgebouwd. In deze proefdierstudie laten wij dus zien 
dat een geleidelijke afbouw van het ballonvolume tijdens het ‘weaningsproces’ leidt tot 
een verbeterde hemodynamiek, coronaire circulatie en metabool profiel. 
Obstructieve malpositie van een IABP-katheter kan logischerwijs leiden tot 
perfusiestoornissen van één, dan wel meerdere viscerale arteriën. Echter, zelfs indien 
implanteurs zich strikt houden aan implantatieprotocollen van fabrikanten ziet men 
veelvuldig problemen ten gevolge van een zogeheten ‘mismatch’ tussen ballonkatheter 
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en de heersende individuele anatomie. Het gebruik van kortere ballonnen op de 
katheters zou mogelijk verbetering kunnen bieden. 
In hoofdstuk 4 tot 7 gaan we in op het gebruik van korte en langere (conventionele) IABP-
katheters met diverse volumina (Zeon Medical Inc., Tokyo, Japan), in een proefdiermodel 
van ischemie-reperfusie. Zo worden een conventionele 40-mL en 35-mL katheter 
vergeleken met twee innovatieve kortere katheters: een 40-mL en een prototype 35-mL 
katheter. Hierbij bestuderen we de effecten op de viscerale circulatie, hemodynamiek en 
de coronaire circulatie en metabolisme. 
In hoofdstuk 4 wordt een zogeheten ‘proof-of-principle’ studie beschreven, waarbij 
ondersteuning middels IABP middels de twee korte katheters (35-mL (prototype) en 40-
mL) wordt vergeleken met een controlegroep. Na 2 uur ischemie bleek er sprake van 
evidente verslechtering van de hemodynamiek, viscerale en coronaire circulatie in alle 
groepen. Tijdens de reperfusie leidde het gebruik van IABP middels de genoemde 
katheters tot een verbetering van zowel de doorbloeding van AMS, nier-arteriën, 
coronairen als ook een verbetering van de hemodynamiek in vergelijking met de niet 
ondersteunde controlegroep. IABP-ondersteuning middels deze kortere ballonkatheters 
ging dus gepaard met klassieke effecten van IABP gebruik: evidente verbetering van de 
hemodynamiek en coronaire circulatie, maar bleek daarnaast ook gunstig voor de 
viscerale circulatie. Derhalve raakten wij benieuwd naar de effecten van IABP-
ondersteuning van deze kortere katheters. 
Volgend op de vragen opgeworpen in hoofdstuk 4 worden er in hoofdstuk 5 twee (één 
korte en één lange) identieke volume (40 mL) IABP-katheters met elkaar vergeleken in de 
eenzelfde setting van ischemie-reperfusie. De effecten op de hemodynamiek, coronaire 
circulatie en metabolisme bleken bij beide katheters gelijk. Desondanks, ondanks 
adequate plaatsing van de katheters bleek de doorbloeding in de AMS enkel te 
verbeteren in de kortere 40-mL ballonvariant, terwijl de langere ballon juist een negatieve 
invloed had op de AMS-doorbloeding. Deze effecten van de kortere katheter bleven 
bestaan wanneer werd geïndexeerd voor gemiddelde bloeddruk, systemische 
vaatweerstand en ‘cardiac output’. Voor de doorbloeding van de nier-arteriën bleek het 
gebruik van beide katheters bevorderlijk, maar waren de effecten van het gebruik van de 
korte katheters significant gunstiger dan die van langere katheters. Mogelijk leid het 
gebruik van kortere katheters tot een meer laminaire bloedstroom ter hoogte van de 
AMS en de nier-arteriën wat deze resultaten zou kunnen verklaren. De resultaten uit deze 
studie hebben mogelijk directe implicaties voor de kliniek: het gebruik van kortere 
katheters kan mogelijk leiden tot een verbetering van de viscerale doorbloeding, zonder 
daarbij compromissen te sluiten ten aanzien van de reguliere effecten van ondersteuning 
middels IABP. 
Hoofdstuk 6 beslaat een proefdierstudie, waarin de prototype 35-mL IABP-katheter wordt 
vergeleken met de conventionele (langere) 40-mL IABP-katheter. Mogelijk zou deze 
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kleinst beschikbare katheter, met in theorie de minste effecten op de viscerale circulatie, 
het gebruik van reguliere (langere) katheters vandaag de dag kunnen vervangen. In de 
reperfusie-fase leidde het gebruik van de prototype 35-mL katheter tot een significante 
verbetering van de bloedvoorziening van de AMS, waarbij de conventionele 40-mL 
katheter juist leidde tot een daling van deze bloedstroom. Toepassing van IABP-therapie 
middels beide katheters leidde daarnaast tot een verbetering van de renale circulatie, 
alhoewel dit bij het gebruik van de prototype 35-mL katheter significant meer was ten 
opzichte van de conventioneel gebruikte 40-mL katheter. De verbeterde viscerale 
doorbloeding van de 35-mL prototype katheter ging desondanks niet ten koste van de 
‘klassieke’ effecten van IABP-therapie. Het gebruik van de prototype 35-mL katheter 
leidde daarnaast tot dezelfde hemodynamische, dan wel coronaire effecten zoals ook 
gezien werd bij het gebruik van de reguliere, langere, 40-mL katheter. 
Aangezien hoofdstuk 6 ons leerde dat het gebruik van de prototype 35-mL IAB in 
vergelijking met de conventioneel gebruikte langere 40-mL katheter, gepaard ging met 
significante viscerale voordelen, zonder daarbij de klassieke hemodynamische en 
coronaire effecten teniet te doen, rees bij ons de vraag in hoeverre de reeds beschikbare 
35-mL katheter eenzelfde profiel zou laten zien. Deze 35-mL ‘lange’ IAB-katheter komt 
met een substantieel kortere ballon in vergelijking met zijn 40-mL equivalent (214 mm 
vs. 243 mm), maar heeft daarnaast eenzelfde diameter (15.1 mL). Ter vergelijk: de 
kortere 40-mL en prototype 35-mL zijn nog korter met een minimaal toegenomen 
diameter (173/ 17,5 mm vs. 162/ 17,1mm). In hoofdstuk 7 vergelijken we derhalve de 
reeds beschikbare 35-mL ‘lange’ IABP-katheter met de drie eerdergenoemde 
alternatieven.   
Alle geteste katheters lieten in dit hoofdstuk eenzelfde hemodynamische  en coronaire 
effecten zien. Ondanks het feit dat de ‘lange’ 35-mL katheter 29 mm korter is dan de 40-
mL ‘lange’ variant, ging het gebruik van deze katheter gepaard met eenzelfde negatieve 
effect op de doorbloeding van de AMS in vergelijking met de twee ‘kortere’ katheters. 
Het gebruik van beide ‘langere’ katheters leidde tot een gelijkwaardige verbeterde 
perfusie van beide nier-arteriën, maar in vergelijking met de twee ‘kortere’ IABP-
katheters bleek dit significant minder. Derhalve impliceren deze bevindingen dat 
veranderingen in de viscerale circulatie ten tijde van IABP-ondersteuning eerder 
gerelateerd zijn aan katheter-ballon lengte en niet aan een kleine toename (5cc) in ballon 
volume.  
Uiteindelijk eindigt dit proefschrift met een algemene discussie, waarbij de resultaten en 
implicaties hiervan op toekomstig onderzoek, katheter ontwikkeling en behandeling 
worden besproken in hoofdstuk 8. 
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